Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.3059
USD
|
+5.77%
|
|
+9.25%
|
-1.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16.14
|
55.03
|
153.2
|
70.41
|
30.46
|
30.77
|
-
|
-
|
Enterprise Value (EV)
1 |
16.14
|
55.03
|
153.2
|
70.41
|
30.46
|
30.77
|
30.77
|
30.77
|
P/E ratio
|
-0.85
x
|
-1.47
x
|
-3.17
x
|
-2.24
x
|
-0.88
x
|
-1.13
x
|
-5.1
x
|
3.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
7.04
x
|
10.8
x
|
5.67
x
|
0.92
x
|
0.49
x
|
EV / Revenue
|
-
|
-
|
-
|
7.04
x
|
10.8
x
|
5.67
x
|
0.92
x
|
0.49
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-2,179,025
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
19,683
|
41,064
|
76,602
|
84,825
|
98,562
|
100,582
|
-
|
-
|
Reference price
2 |
0.8200
|
1.340
|
2.000
|
0.8300
|
0.3090
|
0.3059
|
0.3059
|
0.3059
|
Announcement Date
|
3/27/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
10
|
2.808
|
5.426
|
33.37
|
63.26
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.34
|
-27.4
|
-39.07
|
-31.39
|
-30.94
|
-30.09
|
-7.557
|
13.93
|
Operating Margin
|
-
|
-
|
-
|
-313.85%
|
-1,101.89%
|
-554.64%
|
-22.65%
|
22.01%
|
Earnings before Tax (EBT)
1 |
-14.26
|
-27.4
|
-38.7
|
-30.95
|
-30.16
|
-29.63
|
-7.091
|
14.4
|
Net income
1 |
-15.05
|
-27.41
|
-38.7
|
-30.95
|
-30.16
|
-29.63
|
-7.454
|
13.26
|
Net margin
|
-
|
-
|
-
|
-309.48%
|
-1,074.17%
|
-546.13%
|
-22.34%
|
20.96%
|
EPS
2 |
-0.9700
|
-0.9100
|
-0.6300
|
-0.3700
|
-0.3500
|
-0.2700
|
-0.0600
|
0.0850
|
Free Cash Flow
|
-
|
-25.25
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
10
|
-
|
-
|
-
|
-
|
1
|
1.808
|
0.521
|
3.068
|
0.592
|
4.186
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.67
|
-9.543
|
-8.4
|
0.3843
|
-7.139
|
-16.23
|
-8.383
|
-8.989
|
-8.396
|
-5.171
|
-6.667
|
-4.395
|
-10.84
|
-4.212
|
Operating Margin
|
-
|
-
|
-
|
3.84%
|
-
|
-
|
-
|
-
|
-839.64%
|
-286.05%
|
-1,279.65%
|
-143.25%
|
-1,831.59%
|
-100.62%
|
Earnings before Tax (EBT)
1 |
-12.67
|
-9.542
|
-8.399
|
0.414
|
-7.02
|
-15.94
|
-8.042
|
-8.762
|
-8.299
|
-5.058
|
-6.374
|
-4.166
|
-10.74
|
-3.91
|
Net income
1 |
-12.67
|
-9.542
|
-8.399
|
0.414
|
-7.02
|
-15.94
|
-8.042
|
-8.762
|
-8.299
|
-5.058
|
-6.374
|
-4.166
|
-10.74
|
-3.91
|
Net margin
|
-
|
-
|
-
|
4.14%
|
-
|
-
|
-
|
-
|
-829.91%
|
-279.75%
|
-1,223.42%
|
-135.79%
|
-1,814.86%
|
-93.41%
|
EPS
2 |
-0.1800
|
-0.1800
|
-0.1000
|
0.004900
|
-0.0800
|
-0.1900
|
-0.0900
|
-0.1000
|
-0.0900
|
-0.0600
|
-0.0600
|
-0.0400
|
-0.0900
|
-0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/31/22
|
5/12/22
|
8/9/22
|
11/10/22
|
3/30/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-25.3
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.02
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/27/20
|
3/30/21
|
3/31/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
0.3059
USD Average target price
4
USD Spread / Average Target +1,207.62% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.00% | 30.77M | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|